NCT02678741View on ClinicalTrials.gov

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

October 30, 2019

Study Completion Date

November 13, 2019

Conditions
Metastatic Melanoma
Interventions
DRUG

TLPLDC Vaccine

Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine

Trial Locations (7)

19107

Thomas Jefferson University Hospital, Philadelphia

30342

Northside Hospital, Atlanta

33140

Mount Sinai Comprehensive Cancer Center, Miami Beach

35243

University of Alabama Birmingham Comprehensive Cancer Center, Birmingham

45267

University of Cincinnati Cancer Institute, Cincinnati

90404

John Wayne Cancer Institute/Providence Saint John's Health Center, Santa Monica

98201

Providence Regional Medical Center, Everett

Sponsors

Collaborators (1)

LumaBridge
All Listed Sponsors
collaborator

LumaBridge

INDUSTRY

lead

Elios Therapeutics, LLC

INDUSTRY

NCT02678741 - Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. | Biotech Hunter | Biotech Hunter